Conference
Ximelagatran Versus Warfarin: A Comparison of Bleeding Outcomes in Patients with Nonvalvular Atrial Fibrillation.
Abstract
Abstract
Background: The conventional anticoagulant management of patients with nonvalvular atrial fibrillation (AF) involves warfarin, administered to achieve a target international normalized ratio (INR) of 2.0–3.0. Ximelagatran is a novel oral direct thrombin inhibitor that, unlike warfarin, has a predictable anticoagulant effect and does not require dose adjustments based on the INR. In the SPORTIF III and V trials, …
Authors
Douketis JD; Arneklev K; Goldhaber S; Spandorfer J; Halperin F; Horrow J
Volume
104
Publisher
American Society of Hematology
Publication Date
November 16, 2004
DOI
10.1182/blood.v104.11.1765.1765
Conference proceedings
Blood
Issue
11
ISSN
0006-4971